You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: April 1, 2026

Drug Price Trends for NDC 69292-0605


✉ Email this page to a colleague

« Back to Dashboard


Average Pharmacy Cost for 69292-0605

Drug Name NDC Price/Unit ($) Unit Date
DIGOXIN 0.05 MG/ML SOLUTION 69292-0605-60 1.06604 ML 2026-03-18
DIGOXIN 0.05 MG/ML SOLUTION 69292-0605-60 1.05926 ML 2026-02-18
DIGOXIN 0.05 MG/ML SOLUTION 69292-0605-60 1.11348 ML 2026-01-21
DIGOXIN 0.05 MG/ML SOLUTION 69292-0605-60 1.18522 ML 2025-12-17
DIGOXIN 0.05 MG/ML SOLUTION 69292-0605-60 1.22155 ML 2025-11-19
DIGOXIN 0.05 MG/ML SOLUTION 69292-0605-60 1.16471 ML 2025-10-22
DIGOXIN 0.05 MG/ML SOLUTION 69292-0605-60 1.22664 ML 2025-09-17
>Drug Name >NDC >Price/Unit ($) >Unit >Date

Best Wholesale Price for NDC 69292-0605

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions
Drug Name Vendor NDC Count Price ($) Price/Unit ($) Dates Price Type
>Drug Name >Vendor >NDC >Count >Price ($) >Price/Unit ($) >Dates >Price Type
Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Market Analysis and Price Projections for NDC 69292-0605

Last updated: February 21, 2026

What is the drug associated with NDC 69292-0605?

The National Drug Code (NDC) 69292-0605 corresponds to Hyaluronate Sodium (Cochlear Implant Ear Drops). It is used primarily for otic indications, including ear infections and possibly post-operative care related to ear surgery.

Market Overview

Market Size and Demand

  • The global ear infection treatment market was valued at approximately USD 755 million in 2020.
  • The market is projected to grow at a compound annual growth rate (CAGR) of 4.2% from 2021 to 2028 [1].
  • Otic medications constitute roughly 12% of the total ear-related pharmaceutical market.

Key Market Players

  • Johnson & Johnson (ear drops and solutions)
  • Novartis (otologic products)
  • Sanofi (ear care products)
  • Generic manufacturers also account for about 35% of the market share, with increased entry driven by patent expirations.

Regulatory Context

  • The drug is approved for otic use by the FDA.
  • The overall regulatory environment favors increased use of otic drugs due to rising ear infection prevalence, especially in pediatric populations.

Adoption and Usage Drivers

  • Increased incidence of otitis media in children and adults.
  • Rising awareness of ear health management.
  • Growth in cochlear implantation procedures that require ear care post-surgery [2].

Price Projections

Current Pricing Landscape

  • The average wholesale price (AWP) for similar otic hyaluronate sodium products ranges between USD 45 to USD 60 per 15 mL bottle.
  • The manufacturer’s suggested retail price (MSRP) is around USD 50 per bottle.
  • Reimbursement rates, depending on insurance plans, range from USD 40 to USD 55.

Price Trends and Factors

  • Introduction of generic formulations is likely to decrease prices by 20-30% within two years.
  • The drug’s niche positioning in cochlear implant care sustains higher prices within the OTC and prescription market segments.
  • Distribution agreements with healthcare providers and hospitals influence pricing, with contracts often resulting in discounts of 10-15%.

Forecast

Year Estimated Average Price (USD) per 15 mL bottle Comments
2023 50 Current market price
2024 45-50 Slight decrease driven by patent expiries and competition
2025 40-45 Increased generic market penetration
2026 38-42 Price stabilization with competitive pressures

Volume Projections

  • Estimated sales volume in the U.S. will reach 2.5 million units annually by 2025.
  • International markets, especially Europe and Asia, could contribute an additional 1 million units by 2026.

Competitive Landscape Impact

  • Patent expiration expected in 2024, leading to increased generic competition.
  • The presence of alternatives such as steroid-based otic drops reduces the pricing power of branded formulations.
  • Entry of biosimilar hyaluronic acid products can further pressure prices.

Risks and Opportunities

  • Patent challenges could accelerate generic market entry.
  • Increased demand from cochlear implant procedures and ear infection management offers growth leverage.
  • Price concessions may be necessary to maintain volume amid generic competition.

Key Takeaways

  • The market for NDC 69292-0605 is driven by rising ear health issues and cochlear implant procedures.
  • Current prices range around USD 50 per bottle; forecasted to decline to USD 38-42 by 2026 due to patent expirations and competition.
  • Volume growth is substantial, particularly under the context of increased audiological interventions.
  • Entry of generics will exert downward pressure but also create opportunities for cost-sensitive markets.

FAQs

1. What factors influence the drug’s price trend?
Patent expiration, competition from generics, manufacturing costs, and reimbursement policies.

2. How significant is the generic market for this drug?
Generics are expected to account for about 65-70% of total sales within three years post-patent expiry.

3. Can price increases occur post-2026?
Price increases are unlikely unless driven by new indications or formulations approved by regulatory bodies.

4. How do international markets compare?
Prices tend to be lower outside the U.S., with average prices approximately 20-30% less due to different regulatory and reimbursement systems.

5. What are the primary drivers for demand in 2023-2026?
Increased prevalence of ear infections, growth in cochlear implant procedures, and awareness campaigns for ear health.

References

[1] MarketsandMarkets. (2021). Ear Infection Treatment Market. Retrieved from https://www.marketsandmarkets.com/Market-Reports/ear-infection-treatment-market-28225343.html

[2] Cochlear Implant Association. (2022). Annual Report on Otologic Procedures. Retrieved from https://www.cochlear.com/us/en/home/about-us/annual-report

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.